Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 37.75% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 37.75% decrease from a year earlier, with the FY2025 full-year figure at $11.4 million, down 18.67% from the prior year.
• Total Current Liabilities declined to $8.1 million in Q1 2026 per LCTX's latest filing, from $11.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $25.1 million in Q2 2022 and bottomed at $8.1 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $15.9 million (2023), against an average of $16.0 million.
• Biggest YoY gain for Total Current Liabilities was 271.44% in 2022; the steepest drop was 59.71% in 2022.
• Year by year, Total Current Liabilities stood at $19.0 million in 2022, then decreased by 5.38% to $18.0 million in 2023, then declined by 22.18% to $14.0 million in 2024, then retreated by 18.67% to $11.4 million in 2025, then declined by 28.32% to $8.1 million in 2026.
• Per Business Quant, the three latest LCTX Total Current Liabilities figures stand at $8.1 million (Q1 2026), $11.4 million (Q4 2025), and $9.4 million (Q3 2025).